Icosapent ethyl (IPE) reduces cardiovascular (CV) risk in statin-treated patients with CV disease whether or not they have coronary artery disease (CAD). These are the findings from the latest analysis of data from the REDUCE-IT trial (REDUCE-IT CAD).
Educational partners and supporters
Financial support was provided as a GMG Knowledge Gap Grant from Pfizer Inc.
Financial support was provided as a GMG Knowledge Gap Grant from Pfizer Inc.
Financial support was provided as a GMG Knowledge Gap Grant from Pfizer Inc.
